Back

β-blocker adherence trajectories and 5-year clinical outcomes in PCI-treated ACS patients with LVEF ≥50%: a group-based trajectory modeling analysis

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Contemporary beta‑blocker pharmacotherapy Beta-Blockers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Miaohan Qiu

General Hospital of Northern Theater Command, Shenyang (China)

7 More presentations in this session

Presentation thumbnail
Metoprolol versus bisoprolol in patients with acute myocardial infarction: a target trial emulation study
Doctor T. Yang (Tianjin, CN)
Abstract
Presentation thumbnail
In-hospital beta-blocker initiation is associated with improved survival in AF-HFpEF with tachycardia
Doctor S. Naito (JP)
Abstract
Presentation thumbnail
Beta-blocker therapy after myocardial infarction in the PCI Era: an updated meta-analysis
Doctor J. Aleman (Cebu City, PH)
Abstract
Presentation thumbnail
The range of left ventricular ejection fraction associated with survival benefit from beta-blockers
Professor J. Choi (Seoul, KR)
Abstract
Presentation thumbnail
Impact of beta-blockers after myocardial infarction in patients with preserved or mildly reduced left ventricular ejection fraction: a meta-analysis of randomised trials
Mr L. Neira Chunga (Yurimaguas, PE)
Abstract

Access the full session

Session thumbnail
Contemporary beta‑blocker pharmacotherapy

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic impact of beta-blockers in AMI patients with mid-range left ventricular ejection fraction
21 May 2023
thumbnail
Congress Presentation
Trajectories of physical activity and sedentary behaviour during and after cardiac rehabilitation in patients with acute coronary syndrome
16 April 2021
thumbnail
Congress Presentation
Trajectories of adherence to secondary prevention pharmacotherapy after coronary angiography: a retrospective population-based study
1 September 2025
thumbnail
Congress Presentation
Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources